Living with advanced oesophagogastric adenocarcinoma (a type of cancer in the esophagus or stomach) means facing a difficult road. For patients who have finished their first round of chemotherapy but still have stable disease, finding ways to maintain that stability is vital. This study looked at how adding capecitabine as a maintenance treatment affects these patients compared to just watching the disease closely.
The trial included 266 patients and found that those taking capecitabine saw their cancer stay stable for a longer period of time. Specifically, the median progression-free survival was 5 months with the drug compared to just 2.8 months without it. While the drug did not change the overall survival rates between the two groups, it did significantly improve the amount of time patients lived without their disease getting worse.
It is important to note that while the treatment helped control the cancer's growth, it did come with some risks. About 46% of patients taking capecitabine experienced more severe side effects compared to 29% in the group not taking the drug. Because this was a Phase II trial, these results provide helpful evidence for managing disease progression, but you should always talk to your doctor about how these findings apply to your specific treatment plan.
